Halo Labs (NEO:HALO,OTCQX:AGEEF) announced a definitive agreement to acquire all of the common shares of Precisa Medical Instruments for C$3.8 million in Halo common shares at a price of C$0.28 per share.
As quoted in the press release:
Acquisition and Private Placement Highlights
- The Accu-Dab is a convenient, precise technology to provide on the go dosing of THC or CBD products sublingually for high impact absorption
- The Accu-Dab is a valid option for consumers in search of a non-vaporization mechanism to consume cannabis
- The promising technology will be developed and commercialized by Halo
- Halo will acquire Precisa in addition to concurrently placing C$1,200,000 to fund the development of Accu-Dab and continue business expansion